Unknown

Dataset Information

0

FGFR2 amplification in colorectal adenocarcinoma.


ABSTRACT: FGFR2 is recurrently amplified in 5% of gastric cancers and 1%-4% of breast cancers; however, this molecular alteration has never been reported in a primary colorectal cancer specimen. Preclinical studies indicate that several FGFR tyrosine-kinase inhibitors (TKIs), such as AZD4547, have in vitro activity against the FGFR2-amplified colorectal cell line, NCI-H716. The efficacy of these inhibitors is currently under investigation in clinical trials for breast and gastric cancer. Thus, better characterizing colorectal tumors for FGFR2 amplification could identify a subset of patients who may benefit from FGFR TKI therapies. Here, we describe a novel FGFR2 amplification identified by clinical next-generation sequencing in a primary colorectal cancer. Further characterization of the tumor by immunohistochemistry showed neuroendocrine differentiation, similar to the reported properties of the NCI-H716 cell line. These findings demonstrate that the spectrum of potentially clinically actionable mutations detected by targeted clinical sequencing panels is not limited to only single-nucleotide polymorphisms and insertions/deletions but also to copy-number alterations.

SUBMITTER: Carter JH 

PROVIDER: S-EPMC5701301 | BioStudies | 2017-01-01

REPOSITORIES: biostudies

Similar Datasets

2014-01-01 | S-EPMC4072591 | BioStudies
1000-01-01 | S-EPMC6026866 | BioStudies
2017-01-01 | S-EPMC5430153 | BioStudies
2017-01-01 | S-EPMC5362463 | BioStudies
2016-01-01 | S-EPMC5338732 | BioStudies
2019-01-01 | S-EPMC6510732 | BioStudies
2018-01-01 | S-EPMC5805272 | BioStudies
2016-01-01 | S-EPMC4688307 | BioStudies
2015-01-01 | S-EPMC4385832 | BioStudies
2016-01-01 | S-EPMC5023172 | BioStudies